Management Team

Ms. Jin-Hua Zhang is the Founder, Chairwoman, and CEO of IASO Bio. She graduated from Dongbei University of Finance and Economics with a Master’s degree in Law and is a seasoned securities lawyer. Her career includes significant roles in investment banking and leading securities law firms. As a project leader, she has successfully dual-hatted as both financial advisor and lawyer, overseeing numerous IPOs and M&A projects for Chinese companies. Her expertise spans domestic A-share restructurings, and listings on the Hong Kong Stock Exchange, NASDAQ in the U.S., and the Toronto Stock Exchange in Canada. Since 2003, Ms. Zhang has led nearly 20 M&A projects for publicly listed companies and has facilitated the listings of dozens of companies both domestically and internationally. In 2015, she made an angel investment in an early-stage company focused on CAR-T research and served as a board member.

In 2017, Ms. Zhang founded IASO Bio with the mission of "focusing on innovative biological therapies to bring hope of a cure to patients," dedicated to addressing the unmet clinical needs of patients in China and worldwide. Since its inception, she has led and managed a core team of experts from biotechnology, medicine, antibody development, and pharmaceutical sales fields, all working together on the research, clinical development, production, and commercialization of cell therapy technologies.

Ms. Zhang is also an Executive Director of the Jiangsu Federation of Enterprises and the Jiangsu Entrepreneur Association.

Dr. Yongke Zhang serves as the Chief Scientific Officer at IASO Bio, bringing with him a distinguished track record and profound academic foundation in biopharmaceutical research and development. With over 20 years of R&D experience in biopharmaceuticals and nearly a decade of expertise in oncology and autoimmune disease diagnosis, treatment, and clinical research, Dr. Zhang is a seasoned leader in the field.

Prior to joining IASO Bio, Dr. Zhang gained extensive experience in the U.S. biopharmaceutical industry. He was the co-founder and Chief Scientist of Abcyte Therapeutics, where he spearheaded multiple antibody and multifunctional CAR-T projects, including the development of Narsoplimab injection for the Chinese market. Additionally, he co-founded and served as Senior Director of R&D at Apenexigen, where he led the development of the CD40 agonist immunomodulatory antibody (sotigalimab) aimed at treating advanced pancreatic cancer.

Earlier in his career, Dr. Zhang was the Director of Therapeutic Rabbit Monoclonal Antibody Development at Epitomics, where he oversaw the development of several antibody drugs, including the successful market introduction of the rabbit-derived antibody Brolucizumab. During his tenure at PDL Biopharma (now AbbVie), he worked as a Senior Scientist and Group Leader, contributing to the development of several antibody drugs, most notably Elotuzumab, which successfully reached the market.

Dr. Zhang earned a joint M.D. degree in Clinical Medicine from Peking Medical University and Chiba University in Japan, a Ph.D. in Molecular and Cellular Biology from the University of Tokyo, and completed his postdoctoral research at the DNAX Research Institute (now Merck Research Laboratories) in the United States.

Mr. Hua Zhang serves as the Chief Commercial Officer at IASO Bio. He is a leader with profound insight and significant influence in pharmaceutical marketing, bringing over 20 years of experience in managing marketing and sales departments within the pharmaceutical industry. Mr. Zhang has accumulated extensive practical experience, particularly in the launch and promotion of innovative oncology drugs. Prior to joining IASO Bio, he was the Deputy Chief Commercial Officer at Fosun Kite Biotechnology, where he led the team to successfully launch Yescarta, the first CAR-T therapy approved in China. Before that, he held several key positions, including Specialty Medicine Sales Director at Bayer Pharmaceuticals, North China Marketing Director at Merck Serono, and Sales Director for Pfizer Oncology, where he spearheaded market promotion and commercial operations for the companies' products.

Mr. Zhang holds a Bachelor's degree in Pharmacology from Shanghai Medical College and an MBA from Fudan University.

Dr. Fu is the Chief Financial Officer at IASO Bio, distinguished for his exceptional leadership at the intersection of scientific research and finance. He brings over 20 years of extensive experience in capital markets, financial management, and scientific research. Before joining IASO Bio, Dr. Fu served as Managing Director at Haitong International and Director at Citigroup Global Markets, where he led and facilitated the successful listings of numerous Chinese companies in Hong Kong and the United States, including several in the healthcare sector. Previously, he worked at Davis Polk & Wardwell in Hong Kong and Skadden, Arps, Slate, Meagher & Flom in Palo Alto, focusing on capital market transactions such as IPOs and bond issuances. Earlier in his career, he was a research scientist at Rigel Pharmaceuticals, specializing in immunology and oncology research and drug development.

Dr. Fu holds a Juris Doctor (J.D.) degree from the University of California, Berkeley, a Ph.D. in Molecular Genetics from Washington University in St. Louis, a Master's degree in Immunology from the Shanghai Institute of Cell Biology, Chinese Academy of Sciences, and a Bachelor's degree in Genetics and Genetic Engineering from Fudan University.

Dr. Jie Chen is the Chief Medical Officer at IASO Bio. He has 14 years of experience as an oncologist and over 20 years in the industry. Before joining IASO Bio, Dr. Chen was the Chief Medical Officer at Northland Biologics, where he successfully led the IND application and approval for China's first universal CAR-T product. As Vice President and Head of Medical Affairs at Takeda China, he played a pivotal role in the launch of several new drugs and was deeply involved in the development of the TAK-007 (CAR-NK) product in China. Prior to this, he served as Senior Medical Affairs Director at BMS China, Medical Affairs Director at Pfizer China, and Senior Scientist at 3V Bio.

Dr. Chen holds a Ph.D. from the Army Medical University and completed his postdoctoral research at Fudan University. He is an active member of the CSCO Tumor Biomarker Expert Committee, CSCO Cancer Immunotherapy Expert Committee, an honorary member of the CACA Oncology Drug Research Professional Committee, a member of the CSCO Translational Medicine Expert Committee, and a member of the Jiangsu Pharmaceutical Association's Drug Clinical Evaluation Research Professional Committee.

Dr. Chunli Ren is the Vice President of Regulatory Affairs at IASO Bio, bringing over 15 years of experience in the biopharmaceutical industry. She has extensive expertise in IND and NDA submissions for biological and oncology products. Before joining IASO Bio, Dr. Ren held key positions at several globally renowned pharmaceutical and biotechnology companies, including CStone Pharmaceuticals, GlaxoSmithKline, and Roche. She successfully led the IND/NDA submissions and approvals for more than 20 hematological and solid tumor drugs in both global and Chinese markets.

Dr. Ren holds a Ph.D. in Molecular Biology from the University of Southern California.

Dr. Guang Hu is the Vice President of Research and Development at IASO Bio. He brings over 20 years of experience in translational medicine research and technical product development, with a strong academic background and extensive practical experience in biopharmaceutical R&D. Before joining IASO Bio, Dr. Hu served as the Director of R&D at Wuhan Bioray, focusing on cell therapy technology development. Prior to this, he was the Director of the Bioengineering Research Institute at the Shaoxing Academy of Peking University and the General Manager of Beijing Sinovac Biotech Co., Ltd., where he led multiple biopharmaceutical R&D projects.

Dr. Hu holds a Ph.D. in Molecular Biology from the Institute of Biophysics, Chinese Academy of Sciences, and has conducted postdoctoral research in Tumor Biology at Harvard Medical School and Translational Medicine at Stanford University School of Medicine. He has published over 30 SCI papers in the field of scientific research. Dr. Hu led the preclinical development of the first approved fully human CAR-T product and is the inventor and lead researcher of multiple CAR-T drugs.

Dr. Taochao Tan is the Vice President of Research and Development at IASO Bio. He has over 17 years of experience in the discovery of fully human antibodies, antibody engineering, and the early development of antibody and cell-based drugs. Dr. Tan has led the development of IASO Bio's phage antibody library with a capacity exceeding 2.4E11. Utilizing this platform, he has developed numerous cell therapy drugs, monoclonal antibodies, and bispecific antibodies. Among these, five have entered IIT clinical development, and two have received IND approval for registered clinical trials.

Before joining IASO Bio, Dr. Tan was the Head of Antibody R&D at Eureka Therapeutics in the U.S., where he led the development of Eureka's ALPHA fully human antibody discovery platform. He successfully completed antibody screening for numerous targets, with several antibody sequences being licensed out or entering clinical development.

Dr. Tan holds a Ph.D. in Biochemistry and Molecular Biology from Peking University. He is the first inventor on six granted patents related to antibodies or CAR-T, with dozens of patents pending for antibodies and cell products. He has published multiple articles on CAR-T development in journals such as Signal Transduction and Targeted Therapy and Molecular Therapy.